2Hughes TA, Gaber AO, Montgomery CE. Plasma distribution of cyclosporine within hpoproteins and "in vitro" transfer between very-low-density lipoproteins, low-density lipoproteins, and high-density lipoproteins [J]. Tiler Drug Monit, 1991, 13 (4): 289.
3Lindholm A. Factors influencing the pharmacokinetics of cyclosporine in man [J]. Ther Drug Monit, 1991, 13(6): 465.
4Grevel J. Area-under-the-curve versus trough level monitoring of cyclosporine concentration: critical assessment of dosage adjustment practices and measurement of clinical outcome [J]. Tiler Drug Monit, 1993, 15(6): 488.
5Oellerich M, Armstrong VW. Two-hour cyclosporine concentxation determination: an appropriate tool to monitor neoral therapy [J] Ther Drug Monit, 2002, 24(1): 40.
6Kovarik JM, Mueller EA, van Bree JB, et al. Within-day con sistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients [J]. Ther Drug Monit, 1994, 16(3): 232.
7McLachlan AJ, Tett SE. Effect of metabolic inhibitors on cyclospofine pharmacokinetics using a population approach [J]. Ther Drug Monit, 1998, 20(4): 390.
8Napoli KL, Wang ME, Stepkowski SM, et al. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for ph~annacokinetic interactions [J]. Ther Drug Monit, 1998. 20(2): 123.
9Brattstrom C, Sawe J, Tyden G, et al. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients [J]. Ther Drug Monit, 1997, 19(4): 397.
10Filler G, Lepage N, Delisle B, et al. Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients [J]. Tiler Drug Monit, 2001, 23(5): 514.
